Avexitide cut clinically significant hypoglycemic events by 55% in Phase 3, offering a potential first approved therapy for post-bariatric hypoglycemia.
Key Takeaways
- Avexitide, a glucagon-like peptide-1 receptor (GLP-1R) antagonist, met the primary endpoint in the Phase 3 LUCIDITY trial.
- The once-daily injection reduced Level 2 and Level 3 hypoglycemic events by 55% versus placebo over 16 weeks.
- Post-bariatric hypoglycemia currently has no FDA-approved therapy, making avexitide a potentially first-in-class treatment option.
Data Snapshot
| Item | Details |
|---|---|
| Drug | Avexitide |
| Developer | Amylyx Pharmaceuticals |
| Mechanism | GLP-1 receptor antagonist |
| Indication | Post-bariatric hypoglycemia (PBH) |
| Phase 3 trial | LUCIDITY |
| Trial size | 78 participants |
| Surgery type | Roux-en-Y gastric bypass |
| Primary outcome | Level 2 and Level 3 hypoglycemic events |
| Result | 55% reduction vs. placebo |
| Treatment period | 16 weeks |
| Administration | Once-daily subcutaneous injection |
LUCIDITY enrolled adults with PBH following Roux-en-Y gastric bypass who continued to experience hypoglycemic episodes despite dietary management.
What Happened
Amylyx reported that avexitide met the primary endpoint in the pivotal Phase 3 LUCIDITY study, reducing clinically significant hypoglycemic events by 55% compared with placebo over 16 weeks. The study enrolled 78 adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass. (Reuters report)
* Want to understand the mechanism in more detail?
–> Read our BP Science explainer: [Why Blocking GLP-1 Can Prevent Hypoglycemia After Bariatric Surgery]
The treatment was generally well tolerated, with mainly mild-to-moderate adverse events such as diarrhea and injection-site bruising. Amylyx said it plans to move toward a U.S. marketing application by the end of 2026, with a potential commercial launch in 2027 if approved. (Reuters report)
Why It Matters
PBH can occur after Roux-en-Y gastric bypass when meals trigger an exaggerated hormonal response and excessive insulin release, causing blood glucose to fall to dangerous levels. Severe episodes can lead to cognitive impairment, loss of consciousness or seizures, yet there are currently no FDA-approved treatments specifically for the condition. (Amylyx PBH update)
Avexitide is notable because it works in the opposite direction from the GLP-1 agonists widely used in obesity and diabetes. It blocks the GLP-1 receptor, reducing the excessive insulin secretion that contributes to post-meal hypoglycemia in PBH. (Amylyx clinical background)
This makes avexitide a useful reminder that the same biological pathway can require very different therapeutic strategies depending on the disease context.
BP View
The most interesting part of avexitide is the reversal of a familiar therapeutic concept. GLP-1 activation has transformed obesity and diabetes treatment, but in post-bariatric hypoglycemia, excessive GLP-1 signaling becomes part of the problem.
For patients, the 55% reduction in clinically significant hypoglycemic events is encouraging because these episodes can directly affect independence and everyday safety.
However, a 55% reduction also indicates that a meaningful burden of hypoglycemia may remain despite treatment. The results are therefore encouraging, but they do not suggest that PBH has been fully controlled.
If the Phase 3 data support approval, avexitide could establish a new treatment category in PBH while showing how precisely the same hormone pathway can be targeted in opposite directions for different diseases.
Related Post
For another recent example of an established biological pathway expanding into a new disease area, read our previous analysis of Vyvgart Hytrulo and its Phase 3 success in autoimmune myositis.
About BP
Biopharma Perspective (BP) explains global biopharma news through strategic, clinical and market perspectives.
Leave a Reply